Patent Owners Struck With “Sticker Shock” At PTO’s Proposed Fees
Executive Summary
The Patent and Trademark Office issued a proposed fee schedule as part of its implementation of the Leahy-Smith America Invents Act; post-grant review fees could deter use of the procedure, Lilly’s general counsel says.
You may also be interested in...
Patent Reform Speeds Drug Development, At Least At The Signing Ceremony
President Obama announce seven initiatives to help move ideas from the lab to market as he signs the Leahy-Smith America Invents Act.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.